Specifically, the KEYNOTE-189 (NCT02578680) trial concluded that first-line pembrolizumab plus pemetrexed-platinum substantially improved overall survival (OS) and progression-free survival (PFS) in 410 patients with metastatic nonsquamous NSCLC, regardless of PD-L1 expression or the presence of liver or brain metastases (8). This evidence concerns the gene CD274 and non-small cell lung carcinoma.